|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MSL2 |
Gene summary for MSL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MSL2 | Gene ID | 55167 |
| Gene name | MSL complex subunit 2 | |
| Gene Alias | MSL-2 | |
| Cytomap | 3q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9HCI7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55167 | MSL2 | CCI_1 | Human | Cervix | CC | 7.63e-05 | 6.89e-01 | 0.528 |
| 55167 | MSL2 | CCI_2 | Human | Cervix | CC | 1.78e-15 | 1.18e+00 | 0.5249 |
| 55167 | MSL2 | CCI_3 | Human | Cervix | CC | 4.98e-17 | 8.79e-01 | 0.516 |
| 55167 | MSL2 | C21 | Human | Oral cavity | OSCC | 2.47e-05 | 2.74e-01 | 0.2678 |
| 55167 | MSL2 | C30 | Human | Oral cavity | OSCC | 5.66e-06 | 3.65e-01 | 0.3055 |
| 55167 | MSL2 | C38 | Human | Oral cavity | OSCC | 7.70e-07 | 6.16e-01 | 0.172 |
| 55167 | MSL2 | C43 | Human | Oral cavity | OSCC | 3.93e-06 | 8.60e-02 | 0.1704 |
| 55167 | MSL2 | C46 | Human | Oral cavity | OSCC | 8.55e-03 | 1.76e-01 | 0.1673 |
| 55167 | MSL2 | C06 | Human | Oral cavity | OSCC | 1.05e-06 | 9.50e-01 | 0.2699 |
| 55167 | MSL2 | C08 | Human | Oral cavity | OSCC | 2.59e-11 | 2.36e-01 | 0.1919 |
| 55167 | MSL2 | LN22 | Human | Oral cavity | OSCC | 1.99e-02 | 4.95e-01 | 0.1733 |
| 55167 | MSL2 | LP15 | Human | Oral cavity | LP | 4.33e-08 | 7.68e-01 | 0.2174 |
| 55167 | MSL2 | EOLP-1 | Human | Oral cavity | EOLP | 1.74e-08 | 2.09e-01 | -0.0202 |
| 55167 | MSL2 | NEOLP-3 | Human | Oral cavity | NEOLP | 3.91e-03 | 1.23e-01 | -0.0191 |
| 55167 | MSL2 | SYSMH1 | Human | Oral cavity | OSCC | 2.36e-03 | 7.26e-02 | 0.1127 |
| 55167 | MSL2 | SYSMH2 | Human | Oral cavity | OSCC | 1.20e-05 | 1.19e-01 | 0.2326 |
| 55167 | MSL2 | SYSMH3 | Human | Oral cavity | OSCC | 5.04e-06 | 1.37e-01 | 0.2442 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:00182054 | Cervix | CC | peptidyl-lysine modification | 62/2311 | 376/18723 | 1.04e-02 | 4.97e-02 | 62 |
| GO:00165707 | Oral cavity | OSCC | histone modification | 270/7305 | 463/18723 | 1.59e-17 | 1.50e-15 | 270 |
| GO:00182056 | Oral cavity | OSCC | peptidyl-lysine modification | 216/7305 | 376/18723 | 2.32e-13 | 1.16e-11 | 216 |
| GO:00435434 | Oral cavity | OSCC | protein acylation | 149/7305 | 243/18723 | 1.33e-12 | 5.80e-11 | 149 |
| GO:00183944 | Oral cavity | OSCC | peptidyl-lysine acetylation | 108/7305 | 169/18723 | 4.55e-11 | 1.45e-09 | 108 |
| GO:00064734 | Oral cavity | OSCC | protein acetylation | 124/7305 | 201/18723 | 5.59e-11 | 1.74e-09 | 124 |
| GO:00165734 | Oral cavity | OSCC | histone acetylation | 96/7305 | 152/18723 | 1.35e-09 | 3.29e-08 | 96 |
| GO:00183934 | Oral cavity | OSCC | internal peptidyl-lysine acetylation | 99/7305 | 158/18723 | 1.41e-09 | 3.39e-08 | 99 |
| GO:00064754 | Oral cavity | OSCC | internal protein amino acid acetylation | 100/7305 | 160/18723 | 1.43e-09 | 3.41e-08 | 100 |
| GO:00439674 | Oral cavity | OSCC | histone H4 acetylation | 49/7305 | 67/18723 | 1.45e-08 | 2.91e-07 | 49 |
| GO:00439843 | Oral cavity | OSCC | histone H4-K16 acetylation | 19/7305 | 20/18723 | 2.13e-07 | 3.40e-06 | 19 |
| GO:001820513 | Oral cavity | LP | peptidyl-lysine modification | 136/4623 | 376/18723 | 3.64e-07 | 1.06e-05 | 136 |
| GO:004354312 | Oral cavity | LP | protein acylation | 93/4623 | 243/18723 | 1.65e-06 | 3.86e-05 | 93 |
| GO:001839412 | Oral cavity | LP | peptidyl-lysine acetylation | 68/4623 | 169/18723 | 5.60e-06 | 1.11e-04 | 68 |
| GO:000647312 | Oral cavity | LP | protein acetylation | 78/4623 | 201/18723 | 6.06e-06 | 1.20e-04 | 78 |
| GO:000647512 | Oral cavity | LP | internal protein amino acid acetylation | 63/4623 | 160/18723 | 2.70e-05 | 4.29e-04 | 63 |
| GO:001839312 | Oral cavity | LP | internal peptidyl-lysine acetylation | 62/4623 | 158/18723 | 3.52e-05 | 5.26e-04 | 62 |
| GO:001657312 | Oral cavity | LP | histone acetylation | 60/4623 | 152/18723 | 3.80e-05 | 5.61e-04 | 60 |
| GO:001657014 | Oral cavity | LP | histone modification | 152/4623 | 463/18723 | 4.04e-05 | 5.90e-04 | 152 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MSL2 | SNV | Missense_Mutation | novel | c.1273C>A | p.Pro425Thr | p.P425T | Q9HCI7 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| MSL2 | SNV | Missense_Mutation | c.1603N>A | p.Ala535Thr | p.A535T | Q9HCI7 | protein_coding | deleterious(0.01) | possibly_damaging(0.7) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MSL2 | SNV | Missense_Mutation | c.524C>T | p.Ser175Phe | p.S175F | Q9HCI7 | protein_coding | deleterious(0.02) | possibly_damaging(0.555) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MSL2 | SNV | Missense_Mutation | c.949A>G | p.Met317Val | p.M317V | Q9HCI7 | protein_coding | tolerated(0.41) | benign(0) | TCGA-C8-A12Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MSL2 | insertion | Nonsense_Mutation | novel | c.1271_1272insTTCTGAAGGTAATTAAATTTAGACTATGTAGTATGT | p.Lys424delinsAsnSerGluGlyAsnTerIleTerThrMetTerTyrVal | p.K424delinsNSEGN*I*TM*YV | Q9HCI7 | protein_coding | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| MSL2 | insertion | Nonsense_Mutation | novel | c.260_261insCAACTACAGTAAATAACAGCTTTCTTTTATAGCTGTAT | p.Glu88AsnfsTer5 | p.E88Nfs*5 | Q9HCI7 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | ||
| MSL2 | SNV | Missense_Mutation | novel | c.273G>T | p.Glu91Asp | p.E91D | Q9HCI7 | protein_coding | deleterious(0.05) | benign(0.075) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MSL2 | SNV | Missense_Mutation | novel | c.1405N>G | p.Gln469Glu | p.Q469E | Q9HCI7 | protein_coding | deleterious(0.01) | possibly_damaging(0.888) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| MSL2 | SNV | Missense_Mutation | novel | c.1085N>A | p.Arg362Gln | p.R362Q | Q9HCI7 | protein_coding | tolerated(0.53) | benign(0) | TCGA-VS-A9U7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MSL2 | SNV | Missense_Mutation | c.1316C>A | p.Pro439His | p.P439H | Q9HCI7 | protein_coding | tolerated(0.25) | possibly_damaging(0.534) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |